secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001193125-24-283722
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology merges with Inmagene; Inmagene shareholders to own 55.6% of combined co.
--------------------------------------------------------------------------------

- Pre-PIPE, Inmagene shareholders own ~55.6%, Ikena ~44.4% of combined company.
- PIPE financing of $75M from accredited investors, closing simultaneously with merger.
- Loan agreement: Ikena to lend Inmagene up to $22.5M (initial $7.5M) secured by IMG-007 asset.
- Ikena stockholders to receive CVRs for potential proceeds from pre-merger assets (e.g., IK-595).
- Combined company board: 7 members, 3 from Inmagene, 2 from Ikena, 1 mutual, 1 from PIPE lead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524283722/0001193125-24-283722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312524283722/d889670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-283722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer